FAAH Inhibitor

FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is an inhibitor of FAAH. FAAH-IN-2 is a metabolite of Gefitinib (HY-50895).

AKU-005 is a FAAH and MAGL dual inhibitor with IC₅₀ values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia.

AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH.

AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects.

N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of FAAH for the treatment of pain, inflammation and CNS degenerative disorders.

FAAH inhibitor 1 (compound 3) is a selective reversible FAAH inhibitor. FAAH inhibitor 1 has no off-target activity with respect to other serine hydrolases. FAAH inhibitor 1 is exclusively specific against FAAH in rat brain with an IC₅₀ value of 18 nM and had no missing protein bands in all the other tissues. FAAH inhibitor 1 can be used for neurological disorders research.

FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain.

FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders.

Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC₅₀s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect.

FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC₅₀s of 145 nM and 650 nM for rat and human FAAH, respectively.

Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

SA 47 is a selective fatty acid amide hydrolase (FAAH) inhibitor. SA 47 inhibits FAAH enzyme activity and disrupts the NLRP3-FAAH interaction, promoting K48 ubiquitination and selective autophagic degradation of NLRP3. SA 47 reduces NLRP3 protein levels in macrophages. SA 47 can be used for research on inflammatory diseases associated with NLRP3 protein mutations.

N-​Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 41.8 μM.

JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor.

JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC₅₀ of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments.

SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research.

JP104, a aryl carbamate, is an irreversible FAAH inhibitor with a pIC₅₀ of ~8.

VDM11 is a potent and selective anandamide membrane transporter (AMT) inhibitor. VDM11 inhibits FAAH and MAGL and may act as an alternative FAAH substrate.

Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.

PF-622 is a selective FAAH inhibitor, and can be used for study of analgesic and anxiolytic/antidepressant.